Rehab Cost Savings

• Cost savings of 50-70% compared to US/UK facilities, representing $9,700-$20,000 for 28-30 day residential programs versus US baseline of $27,000-$30,000 and UK baseline of £30,000-£35,000
• 50 JCI-accredited centers providing world-class medical infrastructure, exceeding 20 in Israel and 10 in Germany
• Transparent, all-inclusive pricing with no hidden fees, flexible installment plans, and ability to pay upon clinic arrival
• Comprehensive international patient services including free transfers, medical interpreters, visa assistance, and certified document translation
• Major international insurance acceptance including Allianz, Axa, Anadolu, Acıbadem, and Mapfre with coverage for addiction treatment

Read the full Turkey report →

• Solace Asia offers 28-day residential programs at $6,900 (shared) to $16,900 (premium single), directly meeting Score 4's $10,000-$20,000 benchmark
• Cost savings of 50-65% for standard programs and 70-80% for luxury are solidly in the 50-70% Score 4 range
• Malaysia's therapist salaries average RM 2,329/month (~$580), 8-12 times lower than US/UK equivalents, providing structural pricing advantage
• Multiple program types available (residential, outpatient, IOP, dual diagnosis); MHTC framework provides consumer protection and transparency requirements for accredited facilities
• Limited red flags include uneven pricing transparency (Borneo Recovery, Green Wings, Wave Clinic require direct inquiry), predominantly self-pay model with limited international insurance acceptance, and medical inflation of 10-15% in 2024

Read the full Malaysia report →

• 40–60% cost savings versus US standard programs; 30–50% savings versus UK facilities (PlacidWay comparison)
• Standard 28-day residential programs €7,000–€20,000 (budget options from €5,500); mid-range facilities at €14,000–€20,000
• Strong international patient infrastructure: multilingual teams, visa-free access (90 days) for UK/US/Canadian citizens, English-language treatment widely available
• Multiple financing options: direct private payment, interest-free instalment plans, VAT exemptions (up to 21%) at qualifying facilities; BUPA/AXA insurance accepted at select centres
• Medical detox frequently an additional charge (€4,000–€7,000); pricing opacity at some facilities; US insurance not accepted; family services and aftercare often billed separately

Read the full Spain report →

• Standard 30-day residential programs $4,000-$10,000; luxury/executive $15,000-$30,000, representing 50-70% savings vs US average of $12,500 and 0-60% vs UK private £8,000-£30,000 ($10,000-$38,000)
• Multiple licensed facilities with residential and outpatient programs: Fundación Evoluciona, Fundación Génesis, Narconon Colombia, Casa CAYA; domestic cost base of 1,200,000 COP (~$334)/month for standard programs demonstrates structural advantage
• Outpatient individual therapy sessions at 60,000 COP (~$17), or 50,000 COP (~$14) in packages, representing 80-93% savings vs US rates of $100-$250/hour
• No international insurance agreements at private facilities; patients must self-pay and seek independent reimbursement; most facilities lack published English-language pricing and require direct consultation
• Addiction treatment ecosystem explicitly 'nascent' compared to Colombia's mature medical tourism infrastructure in cosmetic surgery, dentistry, and orthopedics; limited luxury and executive facility options relative to competitors like Thailand

Read the full Colombia report →

• Residential program costs range from $7,000-$13,000 per 30 days (Retorno, IsraRehab, Genesis Treatment), representing 30-50% savings versus US facilities ($15,000-$100,000 per 30 days)
• Majority of facilities do not publish rates online and require direct inquiry, creating significant pricing transparency barriers
• Limited insurance acceptance; predominantly private pay (out-of-pocket) with minimal financing options available
• Established international patient services at multiple facilities (Retorno, Phoenix, Genesis, IsraRehab) with structured programs, airport pickup, and English-language support, serving 60,000+ medical tourists annually
• Small facility market of approximately a dozen Ministry of Health-licensed private options; strong quality assurance but limited competition

Read the full Israel report →

• Standard residential programs offer 65-80% savings but require Polish language: Przy-stań 21-day residential at ~$2,712 USD vs US $12,500–$27,000 for 30-day programs
• English-language option (Zeus Rehab) offers minimal savings: 30-day program €20,000–€35,000 (~$21,300–$37,300 USD) overlaps with US mid-tier and luxury programs
• Only Zeus Rehab has established multilingual concierge services; standard facilities operate exclusively in Polish, creating de facto monopoly for English-speaking international patients
• Pricing transparency inconsistent: The Road Back Home publishes no pricing; ancillary costs at Zeus (naltrexone implants, disulfiram implants) charged separately outside base program cost
• Limited program variety and international infrastructure outside of Zeus: Report emphasizes absence of mid-tier English-language residential option and underdeveloped addiction treatment segment of Poland's medical tourism market

Read the full Poland report →

• 28-day standard residential programs cost approximately $9,500 in Budapest, representing 25-40% savings versus UK rates of £8,000-£12,000 (~$10,000-$15,000)
• Only 2-3 dedicated facilities consistently identified for international patients: Dudits Sobriety Programs, Drug Therapy Center, and Philanthropist Foundation
• Poor pricing transparency: major providers including Drug Therapy Center do not publish pricing online; most facilities require upfront private-pay arrangements
• No all-inclusive medical tourism packages identified; Hungary's medical tourism infrastructure focuses overwhelmingly on dental and cosmetic procedures, not addiction treatment
• No luxury addiction treatment facilities identified despite general Hungarian healthcare cost advantages of 40-70% below Western European levels

Read the full Hungary report →

• KARF Hospital programs: $9,700-$17,700 for 28 days
• Standard facility range: $25,500-$31,500 for 28 days
• Savings estimate: 20-45% compared to mid-range US facilities (report explicitly states this)
• Regional comparison: Thailand offers $3,000-$12,000 for 30 days, significantly undercutting South Korea
• Poor pricing transparency: facilities use 'call for rates' approach, limiting comparison shopping
• Limited medical tourism infrastructure specifically for addiction treatment despite strong general medical tourism
• Some accreditation through Korean Accreditation Program for Hospitals Serving Foreign Patients (KAHF)
• Limited facility options targeting international patients

Read the full South Korea report →

• Domestic mid-tier programs cost $6,500-$8,500 for 30 days (30-68% savings vs US $12,500-$27,000), but conducted primarily in Portuguese with no formal international patient services
• International-marketed facilities exceed US luxury pricing: New Life Florianópolis €47,387/week and Welberry $135,000/30 days offer negative savings
• Only 2-3 facilities serve English-speaking international patients; no established medical tourism infrastructure for addiction treatment, contrasting with strong cosmetics/dentistry tourism sector
• Only ~5% of Brazilians speak English; language barriers are therapeutically counterproductive for addiction treatment requiring relational/linguistic work
• International insurance rarely covers Brazil addiction rehab; pricing transparency poor with 15-30% hidden costs for specialists, labs, medications not bundled in headline rates

Read the full Brazil report →

• Standard private residential programs cost €120-€300/day (€3,600-€9,000/30 days) but major facilities universally require 'price on request' - no transparent published pricing for international patients
• English-speaking international patients typically access premium private clinics at €550-€650/day (€16,500-€19,500/30 days) with substantial add-on costs for medical translation, interpreters, and coordination services, pushing total costs toward mid-range US private program pricing
• Germany lacks a developed medical tourism infrastructure specifically for addiction treatment - unlike orthopedics or oncology, there are no published all-inclusive packages, no dedicated international patient services, and no government medical tourism support for addiction rehabilitation
• Language barriers are fundamental: addiction-specific psychotherapy is conducted almost entirely in German, with English-language therapy teams rare outside major urban expat hubs, limiting therapeutic efficacy for non-German speakers and undermining the cost-quality trade-off

Read the full Germany report →

• Minimal cost savings of 10–25% vs US baseline: 'at most, a 10–25% nominal saving on mid-range standard UK programmes compared to comparable US offerings—too modest to constitute a meaningful cost-savings rationale'
• Hidden costs identified in peer-reviewed 2024 analysis: 'A Thematic Analysis of British Rehabilitation Centers Client Reviews 2020-2024 - Tandfonline - 2024' flagged hidden costs and financial exploitation as recurring themes
• UK as outbound market: 'UK-based addiction treatment providers themselves market Thailand, South Africa, and southern Europe as cost-saving alternatives for British nationals. A 30-day Thai programme ($3,000–$10,000) costs up to 75% less than a comparable UK stay'
• Program costs: Standard 28-day UK private residential £8,000–£22,000 (~$10,000–$27,500); luxury £19,500–£40,000+ (~$24,375–$50,000+)
• Positive international insurance acceptance: Castle Craig, UKAT, Priory, and Delamere accept Aetna, Allianz, AXA, BUPA, Cigna, GeoBlue, TRICARE, and others

Read the full United Kingdom report →

• Standard private 28-day programs range SGD 3,000-20,000 (USD 2,200-14,800); premium programs SGD 27,000-50,000/month (USD 20,000-37,000)
• Mid-to-premium program costs offer 0-26% savings vs US baseline or minimal advantage; regional competitors (Thailand USD 7,500-19,000, Malaysia USD 1,480-5,900) are substantially cheaper
• No major private facilities publish pricing; severe lack of transparent pricing and international patient services infrastructure
• Only one private residential facility opened January 2025; near-zero dedicated medical tourism infrastructure for addiction treatment
• Mandatory reporting obligations, no international insurance acceptance, no government subsidies for international patients, no established medical tourism packages

Read the full Singapore report →

• Sakina Rehabilitation: AED 45,000 (~$12,260 USD) for 30 days private cabin; only 9-bed capacity opened late 2024, with 0-12% savings vs US standard programs ($14,000-27,000)
• Most facilities (Erada, Aspris, Al Amal) do not publish pricing; Sakina excludes psychiatric evaluations, medical detoxification, medications, and aftercare from headline costs
• No medical tourism infrastructure: zero dedicated addiction treatment packages, no facilitator networks, no government incentives, unlike Thailand ($3,000-10,000 30-day programs) or India
• Insurance: addiction-related mental health broadly excluded or capped (Daman's AED 3,500/year insufficient for single residential week); all patients pay entirely out-of-pocket
• Legal and capacity barriers: zero-tolerance drug laws with criminal penalties for possession even of prescription medications; extreme capacity constraints (Sakina 9 beds, New Life Dubai 1 bed) create near-monopoly pricing power

Read the full United Arab Emirates report →

• Standard 30-day residential programs at private facilities cost $25,000-$50,000, with national average of $12,500-$13,475 per person
• Luxury rehabilitation facilities charge $30,000-$100,000 per month, with facilities like Promises in Malibu reaching $120,000 monthly
• Medical detoxification costs $250-$800 per day ($1,750-$5,600 for 7-day program), with average daily cost of $575
• Report explicitly states: 'For international patients, the United States offers no cost advantage whatsoever and instead represents the most expensive option globally for addiction treatment'
• The US is used as the reference baseline for cost comparisons; other countries' cost savings are measured against US/UK facilities

Read the full United States report →

• Only three dedicated rehabilitation facilities in entire country (NCRA at 47-60 bed capacity running at full occupancy, plus one public security facility and Al-Rashid Hospital); none publish residential program costs
• Average drug addiction treatment cost approximately $4,600 USD is actually higher than Turkey at $3,100 USD, representing negative regional competitive positioning
• Zero all-inclusive medical tourism packages for addiction treatment identified; no luxury options, no executive programs, no facility-specific published pricing for international patients
• Fragmented per-session billing model (50-60 JOD/$70-85 per consultation) rather than structured 30-, 60-, or 90-day residential program packages; general medical tourism market in Jordan (70-80% cost advantage for surgical procedures) has not translated to addiction treatment sector
• No documented international patient services, English-language coordinators, online booking systems, or multilingual staff at any addiction treatment facility

Read the full Jordan report →

• The Sanctuary Japan (only international program) charges approximately $50,000 AUD per week (~$31,000–$35,000 USD), making 30-day programs cost $120,000–$150,000+ USD
• The Sanctuary Japan is 2–4× more expensive per week than US luxury rehabilitation ($14,000–$20,000/week) and UK private residential programs
• Public addiction treatment facilities (Kurihama Medical and Addiction Center, Matsuzawa Hospital) do not publish pricing, operate in Japanese only, and are inaccessible to short-stay international patients
• No established medical tourism packages exist for addiction treatment; addiction treatment is entirely absent from Japan Medical Tourism Market reports
• Multiple regional addiction treatment facilitators (Hope Rehab Center Thailand, DARA Rehab) explicitly redirect Japan-based patients to Thailand due to lack of viable local options

Read the full Japan report →